http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105503883-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2015-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105503883-B |
| titleOfInvention | A kind of sitagliptin-nitrate hybrid and its preparation method and application |
| abstract | The invention discloses a sitagliptin-nitrate hybrid and its preparation method and application, belonging to the technical field of medicine preparation. The sitagliptin-nitrate hybrid disclosed in the present invention is quite different from sitagliptin, but still has hypoglycemic activity, and releases NO while lowering blood sugar, thereby improving the NO functional defect induced by diabetes. vascular diseases. The compound ω‑NA‑SG has a significant and sustained hypoglycemic effect on the mouse diabetic model induced by streptozotocin (STZ), can rapidly lower blood sugar, and release NO to increase the level of NO in serum to improve diabetes In the state of NO function defect, it protects the function of vascular endothelium, thereby delaying the occurrence and development of related complications, and is expected to become a new type of multifunctional drug for treating diabetes and its complications. |
| priorityDate | 2015-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 145.